Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07852988
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT07852988
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT07852988. Randomized; double masking; primary purpose treatment. Start 2026-08-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes (T2DM)
- Intervention (Drug)
- Pancreatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Silesian Centre for Heart Diseases
- Collaborator
- Medical University of Silesia
Record details
- Record id
cardio:ct-nct07852988- Content hash
6db12288125c41f0db23f65de99af9ee10d8f82bce0138e4e0009ab719812338